hec89736
Showing 1 - 1 of 1
Relapsed or Refractory B-cell Hematologic Malignancies Trial in Beijing, Nanjing (HEC89736)
Active, not recruiting
- Relapsed or Refractory B-cell Hematologic Malignancies
- HEC89736
-
Beijing, Beijing, China
- +1 more
May 5, 2022